Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

NGNE

Neurogene Inc

Jan 17 • 04:00PM ET

16.60

Dollar change -1.03
Percentage change -5.84	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX RARE BLUE PRTA PTCT AXSM ACAD BTAI FATE RNA

| Held by: VTI IWM VXF IBB VTWO IWO FESM IWN IWC KOMP

Index	RUT	P/E	-	EPS (ttm)	-4.49	Insider Own	16.24%	Shs Outstand	20.98M	Perf Week	-15.22%
Market Cap	348.26M	Forward P/E	-	EPS next Y	-4.22	Insider Trans	3.66%	Shs Float	17.57M	Perf Month	-33.94%
Income	-71.13M	PEG	-	EPS next Q	-1.13	Inst Own	62.09%	Short Float	10.34%	Perf Quarter	-68.83%
Sales	0.93M	P/S	374.47	EPS this Y	-245.34%	Inst Trans	46.25%	Short Ratio	4.59	Perf Half Y	-59.92%
Book/sh	10.56	P/B	1.57	EPS next Y	0.94%	ROA	-56.07%	Short Interest	1.82M	Perf Year	-44.96%
Cash/sh	6.63	P/C	2.51	EPS next 5Y	-	ROE	-66.90%	52W Range	14.44 - 74.49	Perf YTD	-27.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.09%	ROI	-48.18%	52W High	-77.72%	Beta	1.13
Dividend TTM	-	Quick Ratio	9.09	Sales past 5Y	0.00%	Gross Margin	-370.16%	52W Low	14.96%	ATR (14)	2.10
Dividend Ex-Date	-	Current Ratio	9.09	EPS Y/Y TTM	-342.14%	Oper. Margin	-10552.11%	RSI (14)	29.73	Volatility	8.80% 7.94%
Employees	91	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-7689.95%	Recom	1.14	Target Price	52.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-192.49%	Payout	-	Rel Volume	0.40	Prev Close	17.63
Sales Surprise	-	EPS Surprise	2.59%	Sales Q/Q	-	Earnings	Nov 18 AMC	Avg Volume	395.82K	Price	16.60
SMA20	-21.97%	SMA50	-40.06%	SMA200	-53.99%	Trades		Volume	159,310	Change	-5.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$65
Jun-11-24	Initiated	Robert W. Baird	Outperform	$54
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

Nov-18-24 05:25PM	Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire) -42.58% -13.07%
04:14PM	How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week (Investor's Business Daily)
09:48AM	Neurogene Down 36% Extends Losses After Side Effect Derails Its Rett Syndrome Drug (Investor's Business Daily)
06:45AM	Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-12-24 04:10PM	Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal (Investor's Business Daily) -44.08%
10:18AM	Loading…
10:18AM	Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect (Investor's Business Daily)
06:58AM	Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data (GuruFocus.com)
Nov-11-24 04:01PM	Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire)
Nov-05-24 07:54AM	Neurogene Secures $200M for Genetic Therapy Development (TipRanks)
Nov-04-24 07:30AM	Neurogene Announces Oversubscribed $200 Million Private Placement (Business Wire) +43.26%
Oct-21-24 07:30AM	Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome (Business Wire)
Aug-09-24 02:52PM	NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024 (InvestorPlace)
07:30AM	Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
Aug-07-24 07:30AM	Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome (Business Wire)
Jul-02-24 07:30AM	Neurogene to Participate in BMO Genetic Medicines Summit (Business Wire) -5.32%
07:30AM	Loading…
Jul-01-24 07:30AM	Neurogene Announces Addition to Russell 3000 Index (Business Wire) +11.62%
Jun-19-24 09:23AM	Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation (Insider Monkey)
Jun-18-24 09:26AM	Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome (Business Wire) -24.20%
Jun-05-24 07:30AM	Neurogene to Participate in Upcoming Conferences (Business Wire)
Jun-03-24 07:30AM	Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program (Business Wire)
May-10-24 01:54PM	NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates (Business Wire)
May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire) +20.00%
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
07:00AM	Loading…
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Samsara BioCapital GP, LLC	10% Owner	Nov 26 '24	Buy	25.83	48,770	1,259,623	1,717,127	Nov 27 04:39 PM
Cvijic Christine Mikail	President and CFO	Nov 22 '24	Buy	20.48	24,000	491,400	76,844	Nov 25 09:29 PM
McMinn Rachel	Chief Executive Officer	Nov 22 '24	Buy	20.40	47,500	969,000	1,297,859	Nov 25 09:29 PM

Open in Screener

CRGX

CARGO Therapeutics Inc

Jan 17 • 04:00PM ET

12.39

Dollar change +0.39
Percentage change 3.25	%

Healthcare • Biotechnology • USA • NASD

CRGX CARGO Therapeutics Inc daily Stock Chart

Peers: CRSP VRTX GILD NTLA BMRN PFE BLUE EDIT SGMO QURE

| Held by: VTI IWM VXF XBI IWN IBB VTWO SCHA IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-3.55	Insider Own	30.34%	Shs Outstand	45.99M	Perf Week	-8.22%
Market Cap	570.28M	Forward P/E	-	EPS next Y	-4.01	Insider Trans	-0.08%	Shs Float	32.06M	Perf Month	-14.55%
Income	-154.14M	PEG	-	EPS next Q	-0.96	Inst Own	81.36%	Short Float	21.70%	Perf Quarter	-46.20%
Sales	0.00M	P/S	-	EPS this Y	77.72%	Inst Trans	9.58%	Short Ratio	30.18	Perf Half Y	-27.29%
Book/sh	8.72	P/B	1.42	EPS next Y	-8.86%	ROA	-57.80%	Short Interest	6.96M	Perf Year	-35.94%
Cash/sh	8.80	P/C	1.41	EPS next 5Y	-	ROE	-69.81%	52W Range	10.91 - 33.92	Perf YTD	-14.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-35.90%	52W High	-63.47%	Beta	2.66
Dividend TTM	-	Quick Ratio	18.95	Sales past 5Y	0.00%	Gross Margin	-	52W Low	13.57%	ATR (14)	1.26
Dividend Ex-Date	-	Current Ratio	18.95	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	39.66	Volatility	9.80% 9.71%
Employees	-	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	31.38
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-2.14%	Payout	-	Rel Volume	1.06	Prev Close	12.00
Sales Surprise	-	EPS Surprise	20.62%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	230.45K	Price	12.39
SMA20	-9.59%	SMA50	-22.64%	SMA200	-31.32%	Trades		Volume	245,401	Change	3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Initiated	William Blair	Outperform
Jul-22-24	Initiated	H.C. Wainwright	Buy	$33
Jul-08-24	Initiated	Chardan Capital Markets	Buy	$28
Jun-27-24	Initiated	Piper Sandler	Overweight	$37
Dec-05-23	Initiated	Truist	Buy	$34
Dec-05-23	Initiated	TD Cowen	Outperform
Dec-05-23	Initiated	JP Morgan	Overweight	$23
Dec-05-23	Initiated	Jefferies	Buy	$28

Jan-10-25 08:00AM	CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025 (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire)
Dec-17-24 08:00AM	CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 06:34PM	Down -14.13% in 4 Weeks, Here's Why CARGO Therapeutics, Inc. (CRGX) Looks Ripe for a Turnaround (Zacks) +5.53%
Dec-12-24 09:55AM	Bears are Losing Control Over CARGO Therapeutics, Inc. (CRGX), Here's Why It's a 'Buy' Now (Zacks) -8.90%
04:05PM	Loading…
Nov-12-24 04:05PM	CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.98%
Nov-05-24 04:05PM	CARGO Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:23AM	CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity (GlobeNewswire)
Aug-16-24 08:53PM	CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024 (InvestorPlace) +5.61%
06:50PM	Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week (Motley Fool)
Aug-12-24 04:05PM	CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.45%
Jul-10-24 08:00AM	CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet (GlobeNewswire)
Jun-04-24 04:05PM	CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director (GlobeNewswire)
01:56PM	Hedge Fund and Insider Trading News: Bill Ackman, Jim Chanos, Daniel Loeb, Mark Yusko, Citadel LLC, CARGO Therapeutics Inc (CRGX), Apple Inc. (AAPL), and More (Insider Monkey)
May-30-24 06:00AM	Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now (InvestorPlace)
08:05AM	Loading…
May-28-24 08:05AM	CARGO Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -14.33%
08:00AM	CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing (GlobeNewswire)
May-22-24 12:00PM	What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High? (Zacks)
May-14-24 09:54PM	CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +6.55%
04:05PM	CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-15-24 04:05PM	CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors (GlobeNewswire)
Mar-21-24 10:53PM	CRGX Stock Earnings: Cargo Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.23%
04:05PM	CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 04:01PM	CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Jan-03-24 08:05AM	CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -11.58%
Dec-18-23 04:04PM	Alexandria Snags a Pair of Big Bicoastal Lab Leases (Commercial Observer) +13.88%
Dec-13-23 10:51PM	CRGX Stock Earnings: Cargo Therapeutics Reported Results for Q3 2023 (InvestorPlace)
04:05PM	CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results (GlobeNewswire)
Dec-11-23 07:53PM	3 New Stock Listings That Can Deliver Multibagger Returns (InvestorPlace) -5.55%

Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chapman Gina	President & CEO	Sep 18 '24	Option Exercise	5.03	7,166	36,045	111,071	Sep 20 05:24 PM
Chapman Gina	President & CEO	Sep 19 '24	Option Exercise	5.03	2,975	14,964	106,880	Sep 20 05:24 PM
Chapman Gina	President & CEO	Sep 18 '24	Sale	25.09	7,166	179,775	103,905	Sep 20 05:24 PM
Chapman Gina	President & CEO	Sep 19 '24	Sale	25.03	2,975	74,457	103,905	Sep 20 05:24 PM
Radhakrishnan Anup	Chief Financial Officer	Sep 18 '24	Option Exercise	5.03	1,600	8,048	8,046	Sep 20 05:23 PM
Radhakrishnan Anup	Chief Financial Officer	Sep 18 '24	Sale	25.28	1,600	40,452	6,446	Sep 20 05:23 PM
ANUP RADHAKRISHNAN	Officer	Sep 18 '24	Proposed Sale	23.33	14,000	326,620		Sep 18 04:38 PM
GINA CHAPMAN	Director	Sep 18 '24	Proposed Sale	23.33	75,000	1,749,750		Sep 18 04:36 PM
Samsara BioCapital GP, LLC	10% Owner	May 30 '24	Buy	17.00	294,000	4,998,000	4,415,689	Jun 03 09:45 PM

Dollar change -0.26
Percentage change -2.74	%

MLYS Mineralys Therapeutics Inc daily Stock Chart

Peers: FENC AKBA EOLS ARDX ESPR PDSB KNSA ACXP CRVS ATHE

| Held by: VTI IWM VXF IWN VTWO IBB SCHA VHT IWC IWO

Index	RUT	P/E	-	EPS (ttm)	-3.27	Insider Own	52.68%	Shs Outstand	49.76M	Perf Week	-6.38%
Market Cap	459.86M	Forward P/E	-	EPS next Y	-3.85	Insider Trans	-2.37%	Shs Float	23.55M	Perf Month	-24.01%
Income	-153.25M	PEG	-	EPS next Q	-1.08	Inst Own	49.48%	Short Float	7.76%	Perf Quarter	-33.72%
Sales	0.00M	P/S	-	EPS this Y	-85.49%	Inst Trans	0.82%	Short Ratio	8.61	Perf Half Y	-32.16%
Book/sh	4.76	P/B	1.94	EPS next Y	-4.20%	ROA	-56.16%	Short Interest	1.83M	Perf Year	6.08%
Cash/sh	5.30	P/C	1.74	EPS next 5Y	-	ROE	-61.19%	52W Range	7.95 - 16.91	Perf YTD	-24.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-64.68%	52W High	-45.34%	Beta	1.57
Dividend TTM	-	Quick Ratio	8.55	Sales past 5Y	0.00%	Gross Margin	-	52W Low	16.23%	ATR (14)	0.89
Dividend Ex-Date	-	Current Ratio	8.55	EPS Y/Y TTM	-136.84%	Oper. Margin	-	RSI (14)	32.12	Volatility	8.01% 8.03%
Employees	28	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.57
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-104.26%	Payout	-	Rel Volume	1.11	Prev Close	9.50
Sales Surprise	-	EPS Surprise	-30.89%	Sales Q/Q	-	Earnings	Nov 11 AMC	Avg Volume	212.18K	Price	9.24
SMA20	-19.77%	SMA50	-25.01%	SMA200	-26.04%	Trades		Volume	234,826	Change	-2.74%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Jan-09-25 08:29AM	Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials (TipRanks)
Jan-08-25 08:00AM	Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension (GlobeNewswire) -13.71%
Nov-12-24 11:00PM	Mineralys Therapeutics Announces Q3 2024 Results and Updates (TipRanks) -10.32% -6.95%
10:12AM	Q3 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-11-24 04:05PM	Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +6.27%
04:05PM	Loading…
Nov-05-24 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.66%
Nov-04-24 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 (GlobeNewswire)
Oct-30-24 08:00AM	Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)
Sep-25-24 08:00AM	Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Aug-28-24 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-24 04:05PM	Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -22.82%
Aug-05-24 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 (GlobeNewswire) -5.66%
Jul-12-24 07:01PM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares (GuruFocus.com) +6.71%
07:01PM	Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares (GuruFocus.com)
03:11AM	Loading…
Jun-21-24 03:11AM	Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-15-24 02:53AM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares (GuruFocus.com)
Jun-14-24 08:00AM	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors (GlobeNewswire)
02:43AM	Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-03-24 08:00AM	Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-13-24 11:45AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:56AM	MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire) +6.18%
May-02-24 08:00AM	Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 (GlobeNewswire)
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-22-24 10:51AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:53AM	MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... (GuruFocus.com)
07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
Mar-13-24 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 (GlobeNewswire)
Feb-08-24 08:00AM	Mineralys Therapeutics Announces $120 Million Private Placement Financing (GlobeNewswire) +12.51%
Jan-29-24 04:05PM	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference (GlobeNewswire) +6.21%
Jan-17-24 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-04-24 04:05PM	Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer (GlobeNewswire)
Dec-21-23 04:05PM	Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire) +8.30%
Nov-12-23 09:22AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-11-23 11:30AM	Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 (GlobeNewswire)
Nov-09-23 04:05PM	Mineralys Therapeutics to Participate in Three Upcoming Conferences (GlobeNewswire) -9.31% -12.84%
Nov-07-23 05:12PM	Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ... (GuruFocus.com) +8.02% -6.74%
04:05PM	Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 10:00AM	Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting (GlobeNewswire)
Oct-31-23 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023 (GlobeNewswire)
Oct-13-23 04:10PM	Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 (GlobeNewswire) +5.59% +5.19%
Sep-19-23 04:00PM	Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy (GlobeNewswire)
Sep-14-23 04:05PM	Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas (GlobeNewswire)
Sep-11-23 04:05PM	Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023 (GlobeNewswire)
Sep-10-23 07:47AM	Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension (GlobeNewswire)
07:45AM	Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire)
Sep-09-23 05:00AM	CEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Sep-05-23 04:05PM	Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire) -5.57%
09:55AM	Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High? (Zacks)
Aug-29-23 04:05PM	Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 (GlobeNewswire)
Aug-22-23 05:45PM	Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.84%
Aug-07-23 04:05PM	Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.02% +6.96%
Jul-31-23 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023 (GlobeNewswire)
Jul-17-23 04:01PM	Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD) (GlobeNewswire)
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-31-23 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-15-23 04:01PM	Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-23 08:39AM	We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth (Simply Wall St.)
May-02-23 08:00AM	Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension (GlobeNewswire)
May-01-23 08:00AM	Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023 (GlobeNewswire)
Apr-27-23 04:47PM	Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023 (GlobeNewswire)
Mar-15-23 04:01PM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Mar-04-23 04:30PM	Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC (GlobeNewswire)
Mar-01-23 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023 (GlobeNewswire)
Feb-20-23 08:00AM	Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023 (GlobeNewswire)
Feb-17-23 12:08PM	Lab Notes: AnPac dips into real estate with diversification strategy; Mineralys closes $220.8M IPO (American City Business Journals)
Feb-14-23 04:01PM	Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-23 05:16PM	Mineralys, Enlight Trading Debuts Add to Big Week for US IPOs (Bloomberg)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levy Adam Scott	CFO and Secretary	Jan 13 '25	Sale	9.10	10,757	97,864	226,097	Jan 15 09:46 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '25	Option Exercise	0.84	11,367	9,567	158,172	Jan 15 09:45 PM
Congleton Jon	Chief Executive Officer	Jan 13 '25	Sale	9.06	18,333	166,082	877,608	Jan 15 09:44 PM
Congleton Jon	Officer	Jan 13 '25	Proposed Sale	9.06	18,333	166,083		Jan 13 06:34 PM
Levy Adam Scott	Officer	Jan 13 '25	Proposed Sale	9.10	10,757	97,864		Jan 13 06:21 PM
Rodman David Malcom	Chief Medical Officer	Dec 11 '24	Option Exercise	0.54	5,017	2,709	146,008	Dec 13 04:37 PM
Rodman David Malcom	Chief Medical Officer	Nov 11 '24	Option Exercise	0.81	10,043	8,137	146,017	Nov 12 05:25 PM
Rodman David Malcom	Chief Medical Officer	Nov 11 '24	Sale	15.00	5,026	75,398	140,991	Nov 12 05:25 PM
Rodman David Malcom	Officer	Nov 11 '24	Proposed Sale	15.00	5,026	75,398		Nov 12 10:40 AM
Rodman David Malcom	Chief Medical Officer	Nov 06 '24	Option Exercise	1.08	25,482	27,521	161,456	Nov 08 04:21 PM
Rodman David Malcom	Chief Medical Officer	Nov 06 '24	Sale	15.03	25,482	383,066	135,974	Nov 08 04:21 PM
Rodman David Malcom	Officer	Nov 06 '24	Proposed Sale	15.03	25,482	383,067		Nov 06 06:43 PM
Levy Adam Scott	CFO and Secretary	Oct 11 '24	Sale	13.57	10,757	146,004	236,854	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 14 '24	Option Exercise	1.08	5,352	5,780	135,974	Oct 15 04:22 PM
Rodman David Malcom	Chief Medical Officer	Oct 11 '24	Option Exercise	0.54	5,017	2,709	130,622	Oct 15 04:22 PM
Congleton Jon	Chief Executive Officer	Oct 11 '24	Sale	13.52	15,271	206,433	895,941	Oct 15 04:21 PM
Congleton Jon	Officer	Oct 11 '24	Proposed Sale	13.52	15,271	206,434		Oct 11 04:54 PM
Levy Adam Scott	Officer	Oct 11 '24	Proposed Sale	13.57	10,757	146,004		Oct 11 04:48 PM
Rodman David Malcom	Chief Medical Officer	Sep 12 '24	Option Exercise	1.08	6,349	6,857	125,605	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Sep 11 '24	Option Exercise	0.54	5,018	2,710	119,256	Sep 12 04:32 PM
Rodman David Malcom	Chief Medical Officer	Aug 12 '24	Option Exercise	0.84	11,365	9,565	114,238	Aug 13 04:20 PM
Slingsby Brian Taylor	Director	Jul 24 '24	Sale	13.05	550,000	7,177,500	8,644,579	Jul 26 09:45 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Option Exercise	1.08	525	567	103,398	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 16 '24	Sale	15.00	525	7,876	102,873	Jul 18 06:34 PM
Rodman David Malcom	Chief Medical Officer	Jul 12 '24	Option Exercise	1.08	6,349	6,857	102,873	Jul 12 04:39 PM
Rodman David Malcom	Chief Medical Officer	Jul 11 '24	Option Exercise	0.54	5,017	2,709	96,524	Jul 12 04:39 PM
Levy Adam Scott	CFO and Secretary	Jul 11 '24	Sale	13.14	10,757	141,394	247,611	Jul 12 04:37 PM
Congleton Jon	Chief Executive Officer	Jul 11 '24	Sale	13.34	15,746	210,075	911,212	Jul 12 04:36 PM
Congleton Jon	Chief Executive Officer	Jun 17 '24	Sale	12.25	17,766	217,712	958,505	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 18 '24	Sale	11.99	16,607	199,073	941,898	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 20 '24	Sale	11.73	14,940	175,237	926,958	Jun 20 05:44 PM
Congleton Jon	Chief Executive Officer	Jun 13 '24	Sale	12.74	39,961	509,027	992,500	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 12 '24	Sale	12.77	16,607	212,013	1,032,461	Jun 14 06:15 PM
Congleton Jon	Chief Executive Officer	Jun 14 '24	Sale	12.52	16,229	203,163	976,271	Jun 14 06:15 PM
Levy Adam Scott	CFO and Secretary	Jun 11 '24	Sale	12.94	96,815	1,252,718	255,462	Jun 13 05:33 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '24	Option Exercise	1.08	6,349	6,857	89,729	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	Jun 11 '24	Option Exercise	0.54	5,017	2,709	83,380	Jun 13 05:32 PM
Rodman David Malcom	Chief Medical Officer	May 13 '24	Option Exercise	0.84	11,366	9,566	78,363	May 15 04:43 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Option Exercise	1.08	100	108	67,097	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	May 09 '24	Sale	15.00	100	1,500	66,997	May 10 04:17 PM
Rodman David Malcom	Chief Medical Officer	Apr 12 '24	Option Exercise	1.08	6,349	6,857	66,997	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Apr 11 '24	Option Exercise	0.54	5,017	2,709	60,648	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '24	Option Exercise	1.08	6,348	6,856	55,631	Mar 13 05:35 PM
Rodman David Malcom	Chief Medical Officer	Mar 11 '24	Option Exercise	0.54	5,017	2,709	49,283	Mar 13 05:35 PM
Samsara BioCapital GP, LLC	10% Owner	Feb 12 '24	Buy	13.50	555,555	7,499,992	5,074,916	Feb 14 09:06 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '24	Option Exercise	0.84	11,366	9,566	44,266	Feb 13 04:08 PM

Dollar change -0.77
Percentage change -1.75	%

SRRK Scholar Rock Holding Corp daily Stock Chart

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE CARA

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.47	Insider Own	23.65%	Shs Outstand	80.08M	Perf Week	6.52%
Market Cap	4.04B	Forward P/E	-	EPS next Y	-2.22	Insider Trans	-13.93%	Shs Float	71.48M	Perf Month	0.61%
Income	-225.97M	PEG	-	EPS next Q	-0.60	Inst Own	71.67%	Short Float	21.48%	Perf Quarter	48.72%
Sales	0.00M	P/S	-	EPS this Y	-22.05%	Inst Trans	-1.16%	Short Ratio	13.96	Perf Half Y	392.91%
Book/sh	0.99	P/B	43.61	EPS next Y	8.46%	ROA	-105.14%	Short Interest	15.36M	Perf Year	176.65%
Cash/sh	1.49	P/C	29.04	EPS next 5Y	-	ROE	-183.07%	52W Range	6.76 - 46.19	Perf YTD	-0.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.79%	ROI	-161.68%	52W High	-6.61%	Beta	0.52
Dividend TTM	-	Quick Ratio	3.88	Sales past 5Y	-6.57%	Gross Margin	-	52W Low	538.02%	ATR (14)	2.57
Dividend Ex-Date	-	Current Ratio	3.88	EPS Y/Y TTM	-9.56%	Oper. Margin	-	RSI (14)	54.32	Volatility	6.53% 5.83%
Employees	150	Debt/Eq	0.84	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	46.38
Option/Short	Yes / Yes	LT Debt/Eq	0.76	EPS Q/Q	-26.43%	Payout	-	Rel Volume	0.81	Prev Close	43.90
Sales Surprise	-	EPS Surprise	-13.77%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	1.10M	Price	43.13
SMA20	-0.10%	SMA50	12.77%	SMA200	123.86%	Trades		Volume	887,385	Change	-1.75%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65
Jan-06-21	Initiated	JP Morgan	Overweight	$59
Mar-12-20	Initiated	Robert W. Baird	Outperform	$35

Show Previous Ratings

Jan-17-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 06:48PM	Heres Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing (Insider Monkey) +5.21%
Jan-08-25 04:00PM	Scholar Rock Highlights 2025 Strategic Priorities (Business Wire)
Jan-02-25 08:00AM	Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:36PM	Loading…
Dec-04-24 12:36PM	Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%
06:13AM	Biohaven muscle drug misses goal of SMA study, but advances in obesity (BioPharma Dive)
Nov-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 02:08AM	Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 07:00AM	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Business Wire) -5.29%
Nov-11-24 07:07AM	Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Business Wire)
Nov-01-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Business Wire)
Oct-31-24 04:00PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire) -5.14%
08:00AM	Loading…
08:00AM	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Business Wire)
Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%
05:38AM	Here's Why Everybody's Talking About Scholar Rock Right Now (Motley Fool)
Oct-08-24 11:08PM	Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -13.97%
08:29AM	Scholar Rocks SMA Treatment Trials Show Promising Results (TipRanks)
06:43AM	Scholar Rock stocks skyrocket after SMA drug scores at Phase III (Clinical Trials Arena)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +361.99%
04:09PM	Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
03:23PM	Scholar Rock Shares Quadruple On Positive Drug-Study Results (The Wall Street Journal)
11:05AM	Scholar Rock stock surges on positive spinal muscular atrophy treatment data (Investing.com)
11:05AM	Scholar Rock Stock Quadruples on Positive Trial Data (Barrons.com)
09:41AM	Loading…
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
07:00AM	Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-27-24 06:13AM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now (Insider Monkey)
Sep-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.48%
Sep-10-24 08:00AM	Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity (Business Wire) +5.89%
Sep-05-24 12:02AM	Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-04-24 08:00AM	Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer (Business Wire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Aug-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-15-24 04:32AM	Scholar Rocks apitegromab shows promise for non-ambulatory SMA (Clinical Trials Arena)
Aug-09-24 05:05AM	Q2 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-24 07:00AM	Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Jul-23-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Business Wire)
Jul-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-08-24 06:42PM	Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 07:00AM	Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal (Business Wire)
Jun-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 04:00PM	Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting (Business Wire)
May-28-24 08:00AM	Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-22-24 07:00AM	Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity (Business Wire)
May-20-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
May-17-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -12.78%
May-14-24 08:00AM	Scholar Rock to Host Investor Day on May 22, 2024 (Business Wire)
May-07-24 01:53PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q1 2024 (InvestorPlace)
10:19AM	Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss (MT Newswires)
08:52AM	Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
07:00AM	Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress (Business Wire)
Apr-24-24 06:33AM	3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains (InvestorPlace)
Apr-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.08%
Mar-20-24 05:31AM	Scholar Rock Holding Corp Reports Full Year 2023 Financial Results (GuruFocus.com) +8.58%
Mar-19-24 10:52PM	SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023 (InvestorPlace) +14.77%
07:00AM	Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress (Business Wire)
Mar-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.65%
08:18AM	Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks (Insider Monkey)
Feb-28-24 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-16-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.42%
Feb-15-24 08:00AM	Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer (Business Wire)
Feb-06-24 08:00AM	Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management (Business Wire)
Jan-25-24 08:00AM	Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia (Business Wire)
Jan-23-24 08:00AM	Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity (Business Wire)
Jan-22-24 07:00AM	Obesity Drugs Lead to Muscle LossPharma Companies Want to Fix That (The Wall Street Journal)
Jan-18-24 05:01PM	Insider Edward Myles Sells 6,634 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com) -5.10%
Jan-12-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 08:00AM	Scholar Rock Provides Corporate Update and Highlights Priorities for 2024 (Business Wire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace) -6.91%
Dec-30-23 07:01PM	Insider Edward Myles Sells 12,459 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Dec-19-23 08:00AM	Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +5.29%
Dec-15-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Dec-10-23 09:05AM	Insider Sell: COO & CFO Edward Myles Sells 24,914 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
Nov-17-23 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-23 12:32PM	Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:14AM	Scholar Rock Holding Corp (SRRK) Reports Q3 2023 Financial Results (GuruFocus.com)
07:15AM	Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress (Business Wire)
Nov-06-23 09:55AM	Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High? (Zacks)
Nov-03-23 11:52PM	Insider Sell: Edward Myles Sells 35,007 Shares of Scholar Rock Holding Corp (SRRK) (GuruFocus.com)
04:00PM	Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability (Business Wire)
Nov-02-23 08:00AM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK) (Zacks)
Oct-24-23 12:00PM	All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy (Zacks)
Oct-23-23 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (Business Wire)
Oct-19-23 09:55AM	Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet (Zacks)
08:00AM	Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -13.56%
Oct-16-23 04:15PM	Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Business Wire) +5.36% +5.33%
Oct-13-23 12:45PM	Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering (Zacks)
Oct-12-23 04:17PM	Why Scholar Rock Holding Stock Soared Today (Motley Fool) +17.66%
Oct-11-23 08:57PM	Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
05:05PM	Scholar Rock Announces Proposed Public Offering of Common Stock (Business Wire)

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Invus Public Equities, L.P.	10% Owner	Dec 10 '24	Sale	41.65	1,600,000	66,640,000	9,250,005	Dec 12 04:39 PM
Invus Public Equities, L.P.	10% Owner	Nov 25 '24	Sale	38.49	409,433	15,757,639	10,850,005	Nov 27 04:31 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Option Exercise	8.59	6,375	54,761	79,230	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Option Exercise	8.59	2,145	18,426	75,000	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 25 '24	Sale	39.44	6,375	251,399	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 22 '24	Sale	30.01	2,145	64,372	72,855	Nov 26 05:00 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Option Exercise	8.59	2,105	18,082	74,960	Nov 13 04:40 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Nov 11 '24	Sale	30.00	2,105	63,158	72,855	Nov 13 04:40 PM
Myles Edward H	COO & CFO	Oct 08 '24	Option Exercise	10.00	37,187	371,870	198,275	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 08 '24	Sale	34.90	37,187	1,297,659	161,088	Oct 10 06:00 PM
Myles Edward H	COO & CFO	Oct 07 '24	Sale	26.56	206,240	5,477,546	161,088	Oct 07 09:52 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Option Exercise	10.00	30,000	300,000	79,285	Oct 07 09:03 PM
Sacco Tracey	CHIEF COMMERCIAL OFFICER	Oct 07 '24	Sale	25.62	30,000	768,677	49,285	Oct 07 09:03 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Sale	29.25	1,175,713	34,385,672	5,612,896	Oct 07 08:55 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Option Exercise	8.59	109,375	939,531	182,230	Oct 07 08:51 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Oct 07 '24	Sale	27.21	109,375	2,976,468	72,855	Oct 07 08:51 PM
AKKARAJU SRINIVAS	Director	Oct 07 '24	Proposed Sale	29.25	1,175,713	34,385,725		Oct 07 08:43 PM
Tracey Sacco	Officer	Oct 07 '24	Proposed Sale	25.62	30,000	768,693		Oct 07 04:20 PM
Jing Marantz	Officer	Oct 07 '24	Proposed Sale	32.50	120,000	3,900,000		Oct 07 04:18 PM
Edward Myles	Officer	Oct 07 '24	Proposed Sale	32.50	243,427	7,911,378		Oct 07 04:16 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '24	Sale	8.58	1,936	16,611	142,768	Sep 19 08:15 AM
Parlavecchio Caryn	CHRO	Aug 16 '24	Sale	9.33	1,451	13,538	151,988	Aug 19 05:00 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 17 '24	Sale	8.98	2,315	20,800	144,704	Jun 18 05:56 PM
Parlavecchio Caryn	CHRO	Jun 17 '24	Sale	8.98	4,305	38,680	153,439	Jun 18 05:55 PM
Myles Edward H	COO & CFO	Jun 17 '24	Sale	8.98	9,458	84,978	201,518	Jun 18 05:54 PM
Ho Junlin	GENERAL COUNSEL	Jun 17 '24	Sale	8.98	4,695	42,183	204,076	Jun 18 05:53 PM
Myles Edward H	COO & CFO	Feb 16 '24	Sale	15.74	4,744	74,686	210,976	Feb 21 06:13 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 16 '24	Sale	15.74	2,512	39,547	147,019	Feb 20 04:58 PM
Parlavecchio Caryn	CHRO	Feb 16 '24	Sale	15.74	3,751	59,053	157,744	Feb 20 04:52 PM
Ho Junlin	GENERAL COUNSEL	Feb 16 '24	Sale	15.74	3,489	54,928	208,771	Feb 20 04:48 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 16 '24	Sale	15.74	11,614	182,842	352,671	Feb 20 04:46 PM

NGNE

Neurogene Inc

CRGX

CARGO Therapeutics Inc

MLYS

Mineralys Therapeutics Inc

SRRK

Scholar Rock Holding Corp

Upgrade your FINVIZ experience